Advancing TROP-2-Targeted ADCs in HR+ Breast Cancer: Navigating Today and Shaping Tomorrow
Javier Cortes, MD, PhD
Hope S. Rugo, MD, FASCO
Management of HR+, HER2- High-Risk EBC
Erica L. Mayer, MD, MPH
Management of HER2-Low MBC Following First-Line Disease Progression
Peter Schmid, FRCP, MD, PhD
Innovations in Oncology Learning Center: From Guidelines to Practice—Breast Cancer
William J. Gradishar, MD
Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC
Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors
Guideline Recommendations for the Definition and Treatment of HER2-Low Breast Cancer
The Role of HER2-Directed Therapy for Second-Line Treatment of HER2+ Metastatic Breast Cancer
The Evolving Treatment Landscape for MBC: Emerging Therapies
Immunotherapy for TNBC in the Perioperative Setting: Clinical Evidence and Considerations
Expert Viewpoint: Optimizing Breast Cancer Treatment
Emerging Treatment Approaches for EBC
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.